Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.73 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.73 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15467001 | 0.89 | HRH3 (0.87) | HIF1AEPAS1HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL22711526 | 0.84 | HRH3 (0.71) | HIF1AEPAS1HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL19068966 | 0.84 | HRH3 (0.71) | HIF1AEPAS1HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL14129768 | 0.83 | HIF1A (0.56) | HIF1AEPAS1HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL15832718 | 0.83 | ALDH1A1 (0.86) | HIF1AEPAS1HRH3SMN1; SMN2ALDH1A1 | |
| Diethylamine SCHEMBL6244880 | 0.83 | HIF1A (0.59) | HIF1AEPAS1HRH3SMN1; SMN2ALDH1A1 | |
| 4-(4-Chlorobenzyl)Morpholine SCHEMBL4103722 | 0.82 | HRH3 (0.74) | HRH3SMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL13362301 | 0.82 | HRH3 (0.74) | HIF1AEPAS1HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL1640969 | 0.81 | HRH3 (0.74) | HRH3SMN1; SMN2ALDH1A1NCF1 | |
| SCHEMBL5253680 | 0.81 | SIGMAR1 (0.60) | HIF1AEPAS1HRH3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025201453-A1 | MACROCYCLIC COMPOUNDS AS RAS INHIBITORS | BEIGENE (SUZHOU) CO., LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| US-20250171400-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | X-BIOTIX THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-115836077-B | Oxazaspiro derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12227475-B2 | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions | X-BIOTIX THERAPEUTICS, INC. | 2025-02-18 | — | — | US | disclosed |
| EP-4392415-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2024-07-03 | — | — | EP | disclosed |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2024-05-14 | — | — | US | disclosed |
| CN-117980297-A | Substituted aminopyridine compounds as EGFR inhibitors | 柳韩洋行 | 2024-05-03 | — | — | CN | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA (SE) | 2008-05-29 | — | — | US | disclosed |
| WO-2008032191-A2 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032191-A2 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (US) | 2008-03-20 | — | — | WO | disclosed |
| CN-1688545-A | phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234962-A1 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | HIF1A 1198/4885EPAS1 1218/4885HRH3 4098/4885 |
| US-12227475-B2 | Aza-heterocyclyl carboxamide and related compounds and their use in treating medical conditions | AADAC, AZI2, CBX7 | HIF1A 775/4885EPAS1 2637/4885HRH3 1579/4885 |
| US-20250171400-A1 | AZA-HETEROCYCLYL CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | AADAC, AZI2, CBX7 | HIF1A 775/4885EPAS1 2637/4885HRH3 1579/4885 |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | HIF1A 3322/4885EPAS1 1346/4885HRH3 1862/4885 |
| US-20080125431-A1 | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | HIF1A 2732/4885EPAS1 1925/4885HRH3 2617/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | HIF1A 3928/4885EPAS1 822/4885HRH3 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.